Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04920617
Status:
RECRUITING
Last Update Posted:
2023-04-07
First Post:
2021-05-28
Brief Title:
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide in Subjects With RelapsedRefractory Diffuse Large B-Cell Lymphoma
Sponsor:
Organization:
ImmunoVaccine Technologies Inc IMV Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
102
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: